{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:23:27Z","timestamp":1791080607181,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/cmr.0b013e3283403ce9","type":"journal-article","created":{"date-parts":[[2010,9,25]],"date-time":"2010-09-25T09:33:17Z","timestamp":1285407197000},"page":"507-510","source":"Crossref","is-referenced-by-count":75,"title":["Phase 2 open-label study of weekly docosahexaenoic acid\u2013paclitaxel in patients with metastatic uveal melanoma"],"prefix":"10.1097","volume":"20","author":[{"given":"Jade","family":"Homsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agop Y.","family":"Bedikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jen","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy L.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00007611-198105000-00017","article-title":"Prognosis in metastatic choroidal melanoma","volume":"74","author":"Bedikian","year":"1981","journal-title":"South Med J"},{"key":"R3-10-20210129","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/1097-0142(19951101)76:9<1665::AID-CNCR2820760925>3.0.CO;2-J","article-title":"Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors","volume":"76","author":"Bedikian","year":"1995","journal-title":"Cancer"},{"key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","article-title":"Survival of patients with metastases from uveal melanoma","volume":"98","author":"Gragoudas","year":"1991","journal-title":"Ophthalmology"},{"key":"R5-10-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/cncr.11872","article-title":"Prolonged survival after complete resection of metastases from intraocular melanoma","volume":"100","author":"Hsueh","year":"2004","journal-title":"Cancer"},{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/1097-0142(19931001)72:7<2219::AID-CNCR2820720725>3.0.CO;2-J","article-title":"Prognosis and treatment of disseminated uveal melanoma","volume":"72","author":"Kath","year":"1993","journal-title":"Cancer"},{"key":"R7-10-20210129","first-page":"3229","article-title":"Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel","volume":"7","author":"Bradley","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-3659(01)00321-2","article-title":"Tumor targeting by conjugation of DHA to paclitaxel","volume":"74","author":"Bradley","year":"2001","journal-title":"J Control Release"},{"key":"R9-10-20210129","first-page":"3589","article-title":"Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile","volume":"9","author":"Wolff","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R10-10-20210129","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00280-008-0756-0","article-title":"Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, taxoprexin, in resistant solid tumor malignancies","volume":"63","author":"Fracasso","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"R12-10-20210129","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0748-7983(98)91485-8","article-title":"Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy","volume":"24","author":"Salmon","year":"1998","journal-title":"Eur J Surg Oncol"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO;2-R","article-title":"Protracted survival after resection of metastatic uveal melanoma","volume":"89","author":"Aoyama","year":"2000","journal-title":"Cancer"},{"key":"R14-10-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000658-199907000-00001","article-title":"Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients","volume":"230","author":"Curley","year":"1999","journal-title":"Ann Surg"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2214\/ajr.174.2.1740323","article-title":"Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance","volume":"174","author":"Goldberg","year":"2000","journal-title":"AJR Am J Roentgenol"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2214\/ajr.176.1.1760003","article-title":"Radiofrequency ablation of liver","volume":"176","author":"McGahan","year":"2001","journal-title":"AJR Am J Roentgenol"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/BF02725339","article-title":"Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications","volume":"7","author":"Wood","year":"2000","journal-title":"Ann Surg Oncol"},{"key":"R18-10-20210129","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1245\/ASO.2004.08.019","article-title":"Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections","volume":"11","author":"Elias","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"R19-10-20210129","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1245\/ASO.2003.03.026","article-title":"Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients","volume":"10","author":"Pawlik","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"R20-10-20210129","first-page":"6343","article-title":"Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver","volume":"9","author":"Alexander","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R21-10-20210129","first-page":"518","article-title":"A phase I trial of intra-arterial cisplatin (CDDP) with or without embolic occlusion (EO) of the hepatic artery in metastatic ocular melanoma (OM)","volume":"14","author":"El Kassas","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.bjc.6600521","article-title":"Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha and interleukin-2","volume":"87","author":"Becker","year":"2002","journal-title":"Br J Cancer"},{"key":"R23-10-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/030089169408000107","article-title":"Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver: report of a phase II study","volume":"80","author":"Cantore","year":"1994","journal-title":"Tumori"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/00000421-199812000-00008","article-title":"Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials","volume":"21","author":"Flaherty","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"R25-10-20210129","first-page":"394","article-title":"Response to combination chemotherapy of liver metastases from choroidal melanoma compared with cutaneous melanoma","volume":"13","author":"Nathan","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R26-10-20210129","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.1992.10.12.1919","article-title":"A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma","volume":"10","author":"Pyrh\u00f6nen","year":"1992","journal-title":"J Clin Oncol"},{"key":"R27-10-20210129","first-page":"201","article-title":"BOLD+Interferon in treatment of metastatic uveal melanoma: first report of active systemic therapy","volume":"16","author":"Nathan","year":"1997","journal-title":"J Exp Clin Cancer Res"},{"key":"R28-10-20210129","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/cncr.10996","article-title":"Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma","volume":"95","author":"Pyrhonen","year":"2002","journal-title":"Cancer"},{"key":"R29-10-20210129","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0959-8049(03)00132-1","article-title":"Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma","volume":"39","author":"Kivela","year":"2003","journal-title":"Eur J Cancer"},{"key":"R30-10-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00008390-200402000-00010","article-title":"Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma","volume":"14","author":"Bedikian","year":"2004","journal-title":"Melanoma Res"},{"key":"R31-10-20210129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00280-007-0486-8","article-title":"A phase II open-label study of DHA-paclitaxel (taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma","volume":"61","author":"Jones","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R32-10-20210129","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01243894-200611000-00011","article-title":"DHA-paclitaxel (taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial","volume":"1","author":"Payne","year":"2006","journal-title":"J Thorac Oncol"},{"key":"R33-10-20210129","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/CMR.0b013e32832a1e2f","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients","volume":"19","author":"Homsi","year":"2009","journal-title":"Melanoma Res"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0b013e3283403ce9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:23:46Z","timestamp":1621887826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201012000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0b013e3283403ce9","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}